Table 5.

Summary of Efficacy Results From 4 Studies of Duloxetine for the Treatment of Fibromyalgia

	Duloxetine		Placebo
Measure	n	Least Squares Change, Mean (SE)	n	Least Squares Change, Mean (SE)	Between-Group Difference (95% CI at endpoint)	P Value
Brief Pain Inventory score
24-h Average pain severity	774	−1.88 (0.09)	526	−1.12 (0.10)	0.76 (0.50–1.02)	< .001
Least pain severity	774	−1.99 (0.09)	526	−1.31 (0.11)	0.68 (0.40–0.97)	< .001
Worst pain severity	775	−1.36 (0.08)	526	−0.67 (0.10)	0.69 (0.44–0.94)	< .001
Pain right now	775	−1.90 (0.09)	526	−1.20 (0.11)	0.69 (0.42–0.97)	< .001
Pain interference	775	−2.01 (0.09)	526	−1.18 (0.10)	0.83 (0.57–1.08)	< .001
CGI-S score	744	−0.77 (0.04)	506	−0.44 (0.05)	0.34 (0.21–0.46)	< .001
FIQ total score	756	−12.62 (0.61)	513	−8.20 (0.69)	4.43 (2.62–6.23)	< .001
HDRS-17 total score	620	−3.04 (0.19)	390	−2.11 (0.24)	0.93 (0.32–1.54)	< .01
PGI-I score	764	3.19 (0.06)	516	3.60 (0.07)	0.42 (0.24–0.59)	< .001

Abbreviations: CGI-S = Clinical Global Impressions-Severity of Illness scale, FIQ = Fibromyalgia Impact Questionnaire, HDRS-17 = 17-item Hamilton Depression Rating Scale, PGI-I = Patient Global Impressions-Improvement scale.